Abstract 1950P
Background
Neoadjuvant therapy might improve excision and limb salvage rates in locally advanced soft tissue sarcomas (STS). This phase II trial aimed to investigate the safety and activity of neoadjuvant pegylated liposomal doxorubicin (PLD) plus anlotinib in local advanced STS.
Methods
In this prospective, single-center, single-arm phase II study, major eligible criteria were locally advanced, non-metastasis, treatment-naive STS, age at 14-75 years old, pathological stage IIb/III, ECOG PS 0-2. Patients received PLD (50mg/m2, IV, D1, Q3W) and anlotinib (12mg/d, PO, D8-21, Q3W) for 2∼4 cycles. The primary endpoint was objective response rate (ORR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), pathological complete response (ypT0/is ypN0, pCR) and safety.
Results
From November 2020 to November 2022, 45 patients were recruited. The median age was 47 years (range, 15-75) and 19 were female. The predominant histologies included Spindle cell sarcoma 7 (15.56%), Myxofibrosarcoma 5 (11.11%), Myxoid liposarcoma 5 (11.11%), Malignant peripheral nerve sheath tumor 4 (8.89%), Synovial sarcoma 4 (8.89%), Leiomyosarcoma 3 (6.67%). Median treatment cycles of neoadjuvant therapy were 2 (range, 1-4). The ORR and DCR of 29 patients with at least one assessment as Choi criteria was 62.1% and 100%, respectively. Of 39 (86.67%) patients underwent radical resection, 33 (84.62%) patients had an R0 resection. With a median follow-up time of 11.47 months, the median OS were not reached. Median PFS was 14.19 months, and the 1-year OS rate was 84.23%. The limb salvage rates was observed in 39 (100%) patients. The most common adverse events (AEs) of all grade were mucositis oral 19 (42.22%), proteinuria 13 (28.89%), neutropenia 12 (26.67%), and leucopenia 11 (24.44%). Grade 3/4 AEs were 13 (28.89%). PLD plus Anlotinib was well tolerated without significant unexpected toxic effects.
Conclusions
PLD combined with Anlotinib showed a promising efficacy and acceptable toxicity for patients with locally advanced soft tissue sarcomas, suggesting a potential therapeutic option for this population.
Clinical trial identification
NCT04765228.
Editorial acknowledgement
Legal entity responsible for the study
Y. Chen and W. Sun.
Funding
CSPC Ouyi Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1982P - Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Presenter: Jihua Yang
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15